Prostate Cancer | Specialty

ADT and Its Consequences in the Treatment of Prostate Cancer

October 25th 2019

Dr. Bryce on Treatment Selection in Nonmetastatic Castration-Resistant Prostate Cancer

October 25th 2019

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. de Wit on Rationale for Phase III CARD Trial in Metastatic CRPC

October 24th 2019

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Dr. Giri on the PROGRESS Registry for Genetic Testing in Prostate Cancer

October 24th 2019

Veda N. Giri, MD, discusses the PROGRESS registry in genetic testing and counseling for prostate cancer.

Apalutamide Preserves HRQoL in Metastatic Castration-Sensitive Prostate Cancer

October 23rd 2019

Neeraj Agarwal, MD, discusses the TITAN trial and the implications in prostate cancer treatment.

Dr. George on the Changing Treatment Landscape in Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses the changing treatment landscape in prostate cancer.

Coupling Novel Approaches With Chemo in Advanced Prostate Cancer

October 23rd 2019

Daniel J. George, MD, discusses staples of treatment in metastatic prostate cancer as well as novel therapies and emerging strategies in the field.

Dr. Pettaway on Importance of Inclusive Germline Testing in Prostate Cancer

October 22nd 2019

Curtis A. Pettaway, MD, discusses the need to include the genomic data of African American, Asian, and Hispanic men with prostate cancer in national registries.

Genetic Testing Gains Increasingly Significant Role in Prostate Cancer

October 22nd 2019

Leonard G. Gomella, MD, discusses the growth of genetic testing in prostate cancer, how to determine who should undergo testing, and what the future holds in this space.

Dr. Concepcion on Barriers to Genetic Testing in Community Urology Practices

October 17th 2019

Raoul S. Concepcion, MD, FACS, discusses barriers to genetic testing for patients with prostate cancer as identified by community urologists.

Dr. George on Investigational Agents Downstream of the Androgen Receptor in Prostate Cancer

October 17th 2019

Daniel J. George, MD, discusses investigational agents downstream of the androgen receptor in advanced prostate cancer.

Targeted High-Dose Radiation Improves PFS, Progression in Oligometastatic Prostate Cancer

October 16th 2019

In men with oligometastatic prostate cancer, treatment with stereotactic ablative radiation led to significant improvements in progression-free survival, especially in highrisk mutation-negative patients, and confirmed the value of tests for predicting benefit from SABR, according to findings from the phase II ORIOLE trial presented at the 61st Annual Meeting of the American Society for Radiation Oncology.

Dr. Giri on Increasing Awareness of Genetic Testing in Prostate Cancer

October 15th 2019

Veda N. Giri, MD, discusses the increasing need for genetic counseling among men at risk of developing prostate cancer.

Dr. Hussain on Results of the PROfound Trial in mCRPC

October 11th 2019

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Feinberg School of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the results of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Dahut on Using MRI Screening for Prostate Cancer

October 9th 2019

William L. Dahut, MD, discusses multiparametric magnetic resonance imaging as an alternative screening technique to prostate-specific antigen testing in prostate cancer.

Dr. Gomella on the Challenges of Genetic Testing in Prostate Cancer

October 8th 2019

Leonard G. Gomella, MD, discusses the challenges of genetic testing in prostate cancer.

Dr. Agarwal on the Safety Profile of Enzalutamide/Talazoparib in mCRPC

October 7th 2019

Neeraj Agarwal, MD, discusses the safety profile of the combination of enzalutamide and talazoparib in patients with metastatic castration-resistant prostate cancer.

FDA Grants Niraparib Breakthrough Designation for BRCA+ mCRPC

October 4th 2019

The FDA has granted a breakthrough therapy designation to the PARP inhibitor niraparib for the treatment of patients with BRCA1/2–mutant metastatic castration-resistant prostate cancer who have previously received chemotherapy and an androgen receptor inhibitor.

Cabazitaxel Emerges as Third-Line Standard for Metastatic CRPC

October 1st 2019

Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.

Olaparib Doubles rPFS in Heavily Pretreated HRR+ mCRPC

September 30th 2019

Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.